Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Lantern Pharma Inc. (LTRN) had Consolidated Net Income/Loss of $-4.33M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-4.33M |
|
-- |
|
-- |
|
$4.65M |
|
$-4.65M |
|
$0.32M |
|
$-4.33M |
|
$-4.33M |
|
$-4.33M |
|
$-4.33M |
|
|
Consolidated Net Income/Loss |
$-4.33M |
$-4.33M |
|
$-4.65M |
|
$-4.71M |
|
10.79M |
|
10.79M |
|
$-0.40 |
|
$-0.40 |
|
| Balance Sheet Financials | |
$17.20M |
|
$0.04M |
|
$0.22M |
|
$17.42M |
|
$4.88M |
|
-- |
|
$0.01M |
|
$4.90M |
|
$12.52M |
|
$12.52M |
|
$12.52M |
|
10.79M |
|
| Cash Flow Statement Financials | |
$-8.31M |
|
$6.83M |
|
-- |
|
$7.51M |
|
$6.06M |
|
$-1.45M |
|
$0.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.52 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.31M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-34.59% |
|
-34.59% |
|
-24.86% |
|
-34.59% |
|
$1.16 |
|
$-0.77 |
|
$-0.77 |
|